Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Hypertensive target organ damage and the risk for vascular events and all-cause mortality in patients with vascular disease.

Vernooij JW, van der Graaf Y, Nathoe HM, Bemelmans RH, Visseren FL, Spiering W.

J Hypertens. 2013 Mar;31(3):492-99; discussion 499-500. doi: 10.1097/HJH.0b013e32835cd3cd.

PMID:
23303394
2.

Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease.

Vlek AL, van der Graaf Y, Spiering W, Algra A, Visseren FL; SMART study group.

J Intern Med. 2008 Oct;264(4):351-60. doi: 10.1111/j.1365-2796.2008.01970.x. Epub 2008 Jun 3.

3.

Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.

Okin PM.

J Electrocardiol. 2009 Nov-Dec;42(6):584-8. doi: 10.1016/j.jelectrocard.2009.06.020. Epub 2009 Jul 24.

PMID:
19631946
4.

Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.

Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H.

J Hypertens. 2002 Mar;20(3):405-12.

PMID:
11875307
5.

Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension.

Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Porcellati C.

J Am Coll Cardiol. 1998 Feb;31(2):383-90.

6.

Mild renal dysfunction and cardiovascular risk in hypertensive patients.

Leoncini G, Viazzi F, Parodi D, Ratto E, Vettoretti S, Vaccaro V, Ravera M, Deferrari G, Pontremoli R.

J Am Soc Nephrol. 2004 Jan;15 Suppl 1:S88-90. Review.

7.

Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.

de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlöf B, Ibsen H, Kjeldsen SE, Lyle PA, Devereux RB.

J Hum Hypertens. 2007 Aug;21(8):625-32. Epub 2007 May 3.

PMID:
17476291
8.

Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study.

Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JF; ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease).

Ann Intern Med. 2011 Mar 1;154(5):310-8. doi: 10.7326/0003-4819-154-5-201103010-00005.

PMID:
21357908
9.

Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study.

Cea-Calvo L, Conthe P, Gómez-Fernández P, de Alvaro F, Fernández-Pérez C; RICARHD investigators.

Cardiovasc Diabetol. 2006 Nov 3;5:23.

10.

Sex differences in hypertension-related renal and cardiovascular diseases in Italy: the I-DEMAND study.

Muiesan ML, Ambrosioni E, Costa FV, Leonetti G, Pessina AC, Salvetti M, Trimarco B, Volpe M, Pontremoli R, Deferrari G, Rosei EA.

J Hypertens. 2012 Dec;30(12):2378-86. doi: 10.1097/HJH.0b013e328359b6a9.

PMID:
23137952
11.

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.

Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P.

Ann Intern Med. 2003 Dec 2;139(11):901-6.

PMID:
14644892
12.

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.

Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM; LIFE Study Investigators.

J Hypertens. 2006 Apr;24(4):775-81.

PMID:
16531808
13.

Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study.

Tsioufis C, Vezali E, Tsiachris D, Dimitriadis K, Taxiarchou E, Chatzis D, Thomopoulos C, Syrseloudis D, Stefanadi E, Mihas C, Katsi V, Papademetriou V, Stefanadis C.

J Hypertens. 2009 Apr;27(4):744-52. doi: 10.1097/HJH.0b013e32832401ff.

PMID:
19516174
14.

The risk of resting heart rate on vascular events and mortality in vascular patients.

Bemelmans RH, van der Graaf Y, Nathoe HM, Wassink AM, Vernooij JW, Spiering W, Visseren FL; SMARTStudy Group.

Int J Cardiol. 2013 Sep 30;168(2):1410-5. doi: 10.1016/j.ijcard.2012.12.043. Epub 2013 Jan 8.

PMID:
23305859
15.

Impact of lower achieved blood pressure on outcomes in hypertensive patients.

Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB.

J Hypertens. 2012 Apr;30(4):802-10; discussion 810. doi: 10.1097/HJH.0b013e3283516499.

PMID:
22343536
16.

Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.

Vlek AL, van der Graaf Y, Spiering W, Visseren FL; SMART study group.

J Hum Hypertens. 2008 May;22(5):358-65. doi: 10.1038/jhh.2008.5. Epub 2008 Feb 14.

PMID:
18273039
17.

Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.

Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K.

J Hum Hypertens. 2011 Mar;25(3):178-85. doi: 10.1038/jhh.2010.52. Epub 2010 May 27.

PMID:
20505749
18.

[Left ventricular hypertrophy among hypertensive patients with diminished glomerular filtration rate].

Grabysa R, Cholewa M.

Pol Merkur Lekarski. 2008 Oct;25(148):309-14. Polish.

PMID:
19145927
19.

Race and hypertensive target-organ damage in patients from an university-affiliated outpatient care referral clinic in the city of Salvador.

Noblat AC, Lopes MB, Lopes AA.

Arq Bras Cardiol. 2004 Feb;82(2):116-20, 111-5. Epub 2004 Mar 17. English, Portuguese.

20.

The prevalence of obesity-related hypertension and risk for new vascular events in patients with vascular diseases.

Vernooij JW, van der Graaf Y, Visseren FL, Spiering W; SMART study group.

Obesity (Silver Spring). 2012 Oct;20(10):2118-23. doi: 10.1038/oby.2012.76. Epub 2012 Mar 26.

Supplemental Content

Support Center